SM-102 (Synonyms: Lipid H) |
Catalog No.GC48385
One-Click Copy Product Info
|
SM-102 is an ionizable lipid and a key component of lipid nanoparticle (LNP) delivery systems.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2089251-47-6
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
SM-102 is an ionizable lipid and a key component of lipid nanoparticle (LNP) delivery systems. SM-102 is electrically neutral at physiological pH, has low cytotoxicity, and promotes LNP circulation in the body. After entering cells, SM-102 becomes protonated and positively charged in the acidic endosomal environment. The positively charged SM-102 forms ion pairs with anionic phospholipids on the endosomal membrane, disrupts endosomal membrane stability, achieves endosomal escape, and releases mRNA into the cytoplasm for translation. SM-102 can be used in mRNA vaccine delivery, gene therapy, protein replacement therapy, and COVID-19 related research[1-4].
References:
[1] Escalona-Rayo O, Zeng Y, Knol RA, et al. In vitro and in vivo evaluation of clinically-approved ionizable cationic lipids shows divergent results between mRNA transfection and vaccine efficacy. Biomed Pharmacother. 2023 Sep;165:115065.
[2] Naidu GS, Yong SB, Ramishetti S, et al. A Combinatorial Library of Lipid Nanoparticles for Cell Type-Specific mRNA Delivery. Adv Sci (Weinh). 2023 Jul;10(19):e2301929.
[3] McKenzie RE, Minnell JJ, Ganley M, et al. mRNA Synthesis and Encapsulation in Ionizable Lipid Nanoparticles. Curr Protoc. 2023 Sep;3(9):e898.
[4] Zhang L, More KR, Ojha A, et al. Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability. NPJ Vaccines. 2023 Oct 11;8(1):156.
Preparation method of SM-102 for lipid nanoparticles (LNPs)[1-2]
This experimental protocol is compiled based on research content and is for reference only. Please adjust according to actual needs.
(1) Reagent preparation: Dissolve SM-102 in ethanol to prepare a 10mg/mL stock solution. Dissolve cholesterol (Catalog No. GC17398), DSPC (Catalog No. GC41832), and DMG-PEG 2000 (Catalog No. GC39784) separately in anhydrous ethanol. Dissolve mRNA in 50mM sodium citrate buffer (pH=4.0). If LNPs need to be labeled, add the DiD fluorescent probe to the lipid ethanol solution at a concentration of 0.2%.
(2) Preparation of lipid nanoparticles: Add 572μL of 10mg/mL SM-102, 240μL of 10mg/mL cholesterol, 127μL of 10mg/mL DSPC, and 61μL of DMG-PEG 2000 per milliliter of lipid mixture. Mix the solution thoroughly to obtain a clear solution. This mixture contains 10mg of total lipids. The lipid composition is SM-102/cholesterol/DSPC/DMG-PEG at a molar ratio of 50:38.5:10:1.5.
(3) Mixing mRNA with LNPs: The weight ratio of RNA to lipid is 0.05 (wt/wt). Rapid mixing can be achieved by three methods: pipette mixing, vortex mixing, and microfluidic mixing.
a. Pipette mixing method: Aspirate 3mL of mRNA solution and quickly add 1mL of lipid mixture solution (generally using a 1:3 ratio of ethanol lipid mixture to aqueous buffer). Rapidly pipette up and down for 20-30 seconds. Incubate the resulting solution at room temperature for up to 15 minutes.
b. Vortex mixing method: Vortex 3mL of mRNA solution at medium speed on a vortex mixer. Quickly add 1mL of lipid mixture solution into the vortexing solution (usually using a 1:3 ratio of ethanol lipid mixture to aqueous buffer). Continue vortexing the resulting dispersion for 20-30 seconds. Incubate the resulting solution at room temperature for up to 15 minutes.
c. Microfluidic mixing method: Mix 3mL of mRNA buffer with 1mL of lipid mixture solution in a microfluidic device at a total flow rate of 12mL/min (generally using a 1:3 ratio of ethanol lipid mixture to aqueous buffer).
(4) Purification of lipid nanoparticles: After mixing, dialyze the LNPs against PBS (pH=7.4) for 2 hours, sterile filter through a 0.2μm filter, and store at 4°C.
Notes:
(1) LNPs prepared by this method have a particle size of approximately 100nm, a polydispersity index of less than 0.2, and an encapsulation efficiency of up to 98.96%.
(2) LNPs maintain stable particle size and PDI during storage at 4°C for 4 weeks, but mRNA content decreases over time.
(3) For safety and health, please wear a lab coat and disposable gloves during operation.
References:
[1] Escalona-Rayo O, Zeng Y, Knol RA, et al. In vitro and in vivo evaluation of clinically-approved ionizable cationic lipids shows divergent results between mRNA transfection and vaccine efficacy. Biomed Pharmacother. 2023 Sep;165:115065.
[2] Naidu GS, Yong SB, Ramishetti S, et al. A Combinatorial Library of Lipid Nanoparticles for Cell Type-Specific mRNA Delivery. Adv Sci (Weinh). 2023 Jul;10(19):e2301929.
| Cas No. | 2089251-47-6 | SDF | |
| Synonyms | Lipid H | ||
| Canonical SMILES | OCCN(CCCCCCCC(OC(CCCCCCCC)CCCCCCCC)=O)CCCCCC(OCCCCCCCCCCC)=O | ||
| Formula | C44H87NO5 | M.Wt | 710.2 |
| Solubility | Ethanol : ≥ 100 mg/mL (140.81 mM) DMSO ;100 mg/mL (140.81 mM) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.4081 mL | 7.0403 mL | 14.0805 mL |
| 5 mM | 281.6 μL | 1.4081 mL | 2.8161 mL |
| 10 mM | 140.8 μL | 704 μL | 1.4081 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.50% Appearance: A solution in chloroform
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 10 reference(s) in Google Scholar.)